Ademi LLP is investigating Healthcare Trust (NYSE: HTA) for possible breaches of fiduciary duty and other violations of law in its transaction with Healthcare Realty.
Ademi LLP alleges Healthcare Trust’s financial outlook and prospects are excellent and yet Healthcare Trust shareholders will receive only a total implied value of $35.08 per share comprised of a special cash dividend of $4.82 per share and a transaction exchange ratio of 1:1 based on Healthcare Realty’s unaffected price of $30.26 on February 24, 2022. The merger agreement unreasonably limits competing bids for Healthcare Trust by prohibiting solicitation of further bids, and imposing a significant penalty if Healthcare Trust accepts a superior bid. Healthcare Trust insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Healthcare Trust’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Healthcare Trust.